Riskpilot← Back to searchSign inGet full accessPolypeptide Laboratories (Sweden) AB
ABActiveOrg 5563897254Högerudsgatan 21Manufacture of basic pharmaceutical products · NACE 2110Est. 1990350 employees
Revenue 2024
SEK 1,2B
+11% vs 2023
EBITDA margin
25.2%
+40% vs 2023
Equity ratio
24.6%
Financial strength
Net profit 2024
SEK 13,4M
+1445% vs 2023
| Revenue | SEK 1,2B | +11% |
| EBITDA | SEK 297,2M | +40% |
| Net profit | SEK 13,4M | +1445% |
| Total assets | SEK 2,6B | +33% |
| Equity | SEK 651,2M | -31% |
| Employees | 350 | — |
Legal name
Polypeptide Laboratories (Sweden) AB
Org number
5563897254
Legal form
Aktiebolag
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
27 mars 1990
Share capital
SEK 11 500 000
Employees
350 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall tillverka, utveckla och idka handel med peptider och därå baserade kemisk-tekniska produkter, förvärva och upplåta licenser och agenturer för sådan produkter, att idka därmed förenlig verksamhet, samt idka finansiell verksamhet, dock ej sådan verksamhet som avses i lag om bankrörelse eller lag om kreditaktiebolag.
Address
Högerudsgatan 21
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 732 030 | 977 189 | 901 324 | 1 066 269 | 1 179 387 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 241 072 | 388 836 | 243 820 | 212 148 | 297 152 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 241 072 | 388 836 | 243 820 | 212 148 | 297 152 |
| Net financials | −26 362 | 19 069 | 55 813 | −32 024 | 26 066 |
| Profit before tax | 153 853 | 295 769 | 66 336 | 1 516 | 15 460 |
| Tax | −33 059 | −57 490 | −13 155 | −647 | −2 032 |
| Net profit | 120 794 | 238 279 | 53 181 | 869 | 13 428 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 107 484 | 1 435 808 | 1 517 046 | 1 991 348 | 2 642 137 |
| Equity | 645 399 | 883 678 | 936 859 | 937 728 | 651 156 |
| Long-term debt | 0 | 0 | 0 | 256 983 | 932 672 |
| Short-term debt | 280 739 | 338 711 | 314 789 | 417 197 | 602 758 |
| Total debt | 280 739 | 338 711 | 314 789 | 674 180 | 1 535 430 |
EBITDA margin
25.2%
This company
15.8%
Market median
+59% vs market
20202024
Equity ratio
24.6%
This company
38.2%
Market median
-36% vs market
20202024
Return on equity
2.1%
This company
18.4%
Market median
-89% vs market
20202024
Net profit margin
1.1%
This company
8.1%
Market median
-86% vs market
20202024
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20202024
Debt / equity
3.06×
This company
0.62×
Market median
-394% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LE Chief Executive Officer | Chief Executive Officer | 2024 |
SE Chief Auditor | Chief Auditor | 2024 |
| Former (4) | ||
NP Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
AU Chief Auditor | Chief Auditor | 2020 – 2022 |
SJ Chief Auditor | Chief Auditor | 2022 – 2024 |
JF Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Former (9) | ||
| Chairman | 2023 – 2023 | |
| Deputy Board Member | 2020 – 2025 | |
| Board of Directors | 2020 – 2021 | |
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Chairman | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
POLYPEPTIDE GROUP AGPolypeptide Laboratories Holding (PPL) AB
Polypeptide Laboratories (Sweden) AB (this company)Board members of Polypeptide Laboratories (Sweden) AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Elisabeth Berdén | Chief Executive Officer | 0 companies |
| Nils Petter Lybeck | Chief Executive Officer | 0 companies |
| Anna Ulrika Berg Andersson | Chief Auditor | 0 companies |
| Sara Elisabet Königslehner | Chief Auditor | 0 companies |
| Sven Jakob Tenselius | Chief Auditor | 0 companies |
| Jens Fricke | Chief Executive Officer | 0 companies |
| Raoul Bernhardt | Board of Directors | 0 companies |
| Jan Fuhr Miller | Chairman | 0 companies |
| Viveka Maria Persson | Deputy Board Member | 0 companies |
| Folke Flateland | Board of Directors | 0 companies |
| Jane Anne Salik | Chairman | 0 companies |
| Juan Jose Gonzalez Casanova | Chairman | 0 companies |
| Kristian-José Wilhelm Vogel | Deputy Board Member | 0 companies |
| Daniel Gérard M Lasanow | Board of Directors | 0 companies |
| Jan Fuhr Miller | Board of Directors | 0 companies |
| Paulus Ingemar Eriksson | Board of Directors | 0 companies |
| Raymond Gopal De Vré | Chairman | 0 companies |